RETROVIR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Retrovir, and what generic alternatives are available?
Retrovir is a drug marketed by Viiv Hlthcare and is included in four NDAs.
The generic ingredient in RETROVIR is zidovudine. There are twenty-two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the zidovudine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Retrovir
A generic version of RETROVIR was approved as zidovudine by AUROBINDO on September 19th, 2005.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for RETROVIR?
- What are the global sales for RETROVIR?
- What is Average Wholesale Price for RETROVIR?
Summary for RETROVIR
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 4 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 102 |
| Clinical Trials: | 49 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for RETROVIR |
| What excipients (inactive ingredients) are in RETROVIR? | RETROVIR excipients list |
| DailyMed Link: | RETROVIR at DailyMed |
Recent Clinical Trials for RETROVIR
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Phase 2 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Phase 4 |
| International Maternal Pediatric Adolescent AIDS Clinical Trials Group | Phase 4 |
Pharmacology for RETROVIR
US Patents and Regulatory Information for RETROVIR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Viiv Hlthcare | RETROVIR | zidovudine | CAPSULE;ORAL | 019655-001 | Mar 19, 1987 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Viiv Hlthcare | RETROVIR | zidovudine | TABLET;ORAL | 020518-001 | Dec 19, 1995 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Viiv Hlthcare | RETROVIR | zidovudine | INJECTABLE;INJECTION | 019951-001 | Feb 2, 1990 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Viiv Hlthcare | RETROVIR | zidovudine | SOLUTION;ORAL | 019910-001 | Sep 28, 1989 | AA | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Viiv Hlthcare | RETROVIR | zidovudine | TABLET;ORAL | 020518-002 | Oct 4, 1996 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for RETROVIR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Viiv Hlthcare | RETROVIR | zidovudine | SOLUTION;ORAL | 019910-001 | Sep 28, 1989 | ⤷ Sign Up | ⤷ Sign Up |
| Viiv Hlthcare | RETROVIR | zidovudine | TABLET;ORAL | 020518-002 | Oct 4, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Viiv Hlthcare | RETROVIR | zidovudine | CAPSULE;ORAL | 019655-001 | Mar 19, 1987 | ⤷ Sign Up | ⤷ Sign Up |
| Viiv Hlthcare | RETROVIR | zidovudine | TABLET;ORAL | 020518-002 | Oct 4, 1996 | ⤷ Sign Up | ⤷ Sign Up |
| Viiv Hlthcare | RETROVIR | zidovudine | INJECTABLE;INJECTION | 019951-001 | Feb 2, 1990 | ⤷ Sign Up | ⤷ Sign Up |
| Viiv Hlthcare | RETROVIR | zidovudine | TABLET;ORAL | 020518-001 | Dec 19, 1995 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for RETROVIR
See the table below for patents covering RETROVIR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Hungary | 203971 | PROCESS FOR PRODUCING SYNERGETIC COMBINATION PHARMACEUTICAL COMPOSITIONS COMPRISING 3'-AZIDO-3'-DEOXYTHYMIDINE AND ONE MORE ACTIVE INGREDIENT | ⤷ Sign Up |
| Denmark | 167377 | ⤷ Sign Up | |
| African Regional IP Organization (ARIPO) | 8600027 | ⤷ Sign Up | |
| Germany | 196185 | ⤷ Sign Up | |
| Ireland | 73219 | Therapeutic nucleosides | ⤷ Sign Up |
| German Democratic Republic | 262802 | VERFAHREN ZUR HERSTELLUNG EINER PHARMAZEUTISCHEN FORMULIERUNG | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for RETROVIR
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0513917 | SPC/GB98/019 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: A COMBINATION COMPRISING LAMIVUDINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND ZIDOVUDINE; REGISTERED: UK EU/1/98/058/001 19980318; UK EU/1/98/058/002 19980318 |
| 0513917 | C980018 | Netherlands | ⤷ Sign Up | PRODUCT NAME: LAMIVUDINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN ZIDOVUDINE; REGISTRATION NO/DATE: EU/1/98/058/001-002 19980318 |
| 0513917 | 98C0020 | Belgium | ⤷ Sign Up | PRODUCT NAME: LAMIVUDINE/ZIDOVUDINE; REGISTRATION NO/DATE: EU/1/98/058/001 19980318 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
